Last reviewed · How we verify
IG3018
At a glance
| Generic name | IG3018 |
|---|---|
| Sponsor | Intelligem Therapeutics Australia Pty Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IG3018 CI brief — competitive landscape report
- IG3018 updates RSS · CI watch RSS
- Intelligem Therapeutics Australia Pty Ltd. portfolio CI